The 2022 Technology Showcase, organized by the National Cancer Institute Technology Transfer Center and the Frederick National Laboratory, is scheduled for the afternoon of September 7. – Free, half-day hybrid [….]
2022 Technology Showcase
Tech Opportunity Webinar: CytoSig, a Novel Software Platform Predictor of Cytokine Signaling Activity & Targeted Discovery
Published on :Join us for a TTC-hosted webinar and hear from NCI’s Dr. Peng Jiang about a new Cytokine Signaling Analyzer called “CytoSig.” This novel software-based platform provides both a database of [….]
Partnering Webinar: Detection of SARS-CoV-2 and other RNA Viruses Using a Novel Improved RT-qPCR Method that Increases Detection Sensitivity and Improves Safety
Published on :NIH researchers will highlight a novel Covid-19 diagnostic technology from the National Eye Institute (NEI). NEI is seeking partners for collaboration and licensing to accelerate technology development and clinical benefit. [….]
NCI Tech Opportunity Webinar: Use of Tempol as an Antiviral Therapeutic Against COVID-19
Published on :Attendees will hear from NICHD’s Dr. Tracey Rouault about the potential to formulate the compound, Tempol, into a preventative and oral treatment for COVID-19. The replication of the SARS-CoV-2’s genome [….]
PODD: Partnership Opportunities in Drug Delivery
Published on :Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]
Luke Thorstenson Appointed Director of Business Development for Orgenesis Inc.
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore
2021 Technology Showcase
Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, [….]
NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV
TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]
NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”
The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.
5 Questions with Stephen M. Jackson, Staff Scientist – Immunology, ABL, Inc.
Born and raised in gang-infested South Central Los Angeles, I was surrounded by compassionate and risk-taking individuals who recognized and fertilized my love, talent, and academic prowess. Collectively my tribe, for it takes one to raise one, helped provide me with unimaginable opportunities to excel and continue the fight for an abundant life through health, social awareness, and artistic expression. I, a Man who is also Bold and Black, am a product of their courage, compassion, endurance, vision, and love – Stephen M. Jackson, PhD